Company / Cash & Equivalents
ArriVent BioPharma, Inc. Cash & Equivalents History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$74.3M
FY2024
5-year range
$74.3M / $150.4M
FY2023-FY2024
Trend
-50.6%
vs FY2023
Sector context
#163 of 207
Health Care
What the data says
ArriVent BioPharma, Inc.'s cash & equivalents of $74M is lower than 79% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$74M in FY2024.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 207This company $74.3M Sector average $669.5M
▼
-88.9% below sector average
Key checks
Key Insights
- In FY2024, cash & equivalents decreased 50.6% year-over-year.
- Ranks #163 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $74.3M | -50.6% |
| FY2023 | $150.4M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026